Treatment strategy, overall survival and associated risk factors among patients with unresectable stage IIIB/IV non-small cell lung cancer in China (2015–2017): A multicentre prospective study

Shi, Yuankai; Zhang, Xin; Wu, Gang; Xu, Jianping; He, Yong; Wang, Dong; Huang, Cheng; Chen, Mingwei; Yu, Ping; Yu, Yan; Li, Wei; Li, Qi; Hu, Xiaohua; Xia, Jinjing; Bu, Lilian; Yin, Angela; Zhou, Yong‐Wu

doi:10.1016/j.lanwpc.2022.100452

Cited by 6 publications

(5 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Univariate analyses revealed that smoking, N_stage, T_stage and type of IC regimen where independent risk factors for OS, while multivariate analyses showed that drinking, and T_stage were risk factors for PFS. These findings are consistent with results by Shi et al [ 23 ] , and Crenkova et al [ 24 ] Our results also showed that IC treatment with DC regime showed better OS than the other drug combinations, consistent with Aydiner et al [ 25 ] , and in line with the recommendation by the ASCO. [ 10 ] However, several drug combinations are in clinical trials in attempts to find combinations that can be as effective as DC and at the same time lessen toxicities.…”

Section: Discussionsupporting

confidence: 93%

Optimum cycles of induction chemotherapy in concurrent chemo-radiotherapy management of unresectable stage III non-small cell lung cancer: Results from a single institutional database

et al. 2023

View full text Add to dashboard Cite

Induction chemotherapy (IC) prior to concurrent chemo-radiotherapy is the recommended treatment for unresectable stage III non-small cell lung cancer (NSCLC). However, the optimum number of IC cycles for improved survival outcomes is still not known. Here, we assessed the efficacy of 2 or more cycles of IC for unresectable stage III NSCLC patients from our hospital. Data on unresectable stage III NSCLC patients treated with IC + concurrent chemo-radiotherapy at our hospital between 2018 and 2022 were retrieved and analyzed, and survival outcomes compared between IC = 2 and IC > 2 patients. Univariate and multivariate Cox regression, and Chi-square or Fisher exact test were used to assess prognosis and acute toxicity profiles. One hundred twenty-six patients were recruited; 90 for IC = 2 and 36 for IC > 2. Median follow-up time was 26 months [IQR 16-38]. Three-year overall survival was not statistically significant between the 2 groups (77.8% vs 75.0%, P = .453). Distant metastasis free survival, loco-regional recurrence free survival and progression free survival were also not significant, (90.0% vs 86.1%, P = .068), 97.8% vs 97.2%, P = .056), and (73.3% vs 66.7%, P = .446) respectively. Univariate and multivariate Cox regression analysis revealed smoking, T_stage, N_stage, and IC_regimen as independent prognostic factor for overall survival, while drinking and T_stage were risk factors for progression free survival. In summary, 2 cycles of platinum-based IC was effective for stage III unresectable NSCLC and adding more than 2 cycles did not offer extra survival benefits.

show abstract

Section: Discussionsupporting

confidence: 93%

Optimum cycles of induction chemotherapy in concurrent chemo-radiotherapy management of unresectable stage III non-small cell lung cancer: Results from a single institutional database

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Non-small cell lung cancer (NSCLC) accounts for more than 80% of cases and is considered a heterogeneous disease [ 3 ]. With the discovery of the epidermal growth factor receptor (EGFR) gene and continuous research on tyrosine kinase inhibitor (TKI), treatment of advanced or metastatic patients with NSCLC has been greatly improved, and the overall survival has been extended [ 4 , 5 ]. EGFR-TKI is the standard first-line treatment for NSCLC patients with EGFR mutations [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Predicting epidermal growth factor receptor mutations in non-small cell lung cancer through dual-layer spectral CT: a prospective study

Li,

Qi,

Cheng

et al. 2024

Insights Imaging

View full text Add to dashboard Cite

Objective To determine whether quantitative parameters of detector-derived dual-layer spectral computed tomography (DLCT) can reliably identify epidermal growth factor receptor (EGFR) mutation status in patients with non-small cell lung cancer (NSCLC). Methods Patients with NSCLC who underwent arterial phase (AP) and venous phase (VP) DLCT between December 2021 and November 2022 were subdivided into the mutated and wild-type EGFR groups following EGFR mutation testing. Their baseline clinical data, conventional CT images, and spectral images were obtained. Iodine concentration (IC), iodine no water (INW), effective atomic number (Zeff), virtual monoenergetic images, the slope of the spectral attenuation curve (λHU), enhancement degree (ED), arterial enhancement fraction (AEF), and normalized AEF (NAEF) were measured for each lesion. Results Ninety-two patients (median age, 61 years, interquartile range [51, 67]; 33 men) were evaluated. The univariate analysis indicated that IC, normalized IC (NIC), INW and ED for the AP and VP, as well as Zeff and λHU for the VP were significantly associated with EGFR mutation status (all p < 0.05). INW(VP) showed the best diagnostic performance (AUC, 0.892 [95% confidence interval {CI}: 0.823, 0.960]). However, neither AEF (p = 0.156) nor NAEF (p = 0.567) showed significant differences between the two groups. The multivariate analysis showed that INW(AP) and NIC(VP) were significant predictors of EGFR mutation status, with the latter showing better performance (p = 0.029; AUC, 0.897 [95% CI: 0.816, 0.951] vs. 0.774 [95% CI: 0.675, 0.855]). Conclusion Quantitative parameters of DLCT can help predict EGFR mutation status in patients with NSCLC. Critical relevance statement Quantitative parameters of DLCT, especially NIC(VP), can help predict EGFR mutation status in patients with NSCLC, facilitating appropriate and individualized treatment for them. Key Points Determining EGFR mutation status in patients with NSCLC before starting therapy is essential. Quantitative parameters of DLCT can predict EGFR mutation status in NSCLC patients. NIC in venous phase is an important parameter to guide individualized treatment selection for NSCLC patients. Graphical Abstract

show abstract

“…4 A recent prospective study in China analyzed the survival of patients with unresectable stage ⅢB/Ⅳ NSCLC treated according to the choice of their physicians and reported that the median OS was 23.2 months (95% confidence interval [CI], 19.5–25.5 months) and the 1- and 3-year OS rate was 68.9% and 39.0%, respectively. 5 …”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of utidelone for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer who have failed standard second-line treatment: A phase 2 clinical trial (BG01-1801)

Shi,

Chen,

Zhao

et al. 2024

Cancer Pathogenesis and Therapy

View full text Add to dashboard Cite

Treatment strategy, overall survival and associated risk factors among patients with unresectable stage IIIB/IV non-small cell lung cancer in China (2015–2017): A multicentre prospective study

Cited by 6 publications

References 39 publications

Optimum cycles of induction chemotherapy in concurrent chemo-radiotherapy management of unresectable stage III non-small cell lung cancer: Results from a single institutional database

Optimum cycles of induction chemotherapy in concurrent chemo-radiotherapy management of unresectable stage III non-small cell lung cancer: Results from a single institutional database

Predicting epidermal growth factor receptor mutations in non-small cell lung cancer through dual-layer spectral CT: a prospective study

Efficacy and safety of utidelone for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer who have failed standard second-line treatment: A phase 2 clinical trial (BG01-1801)

Contact Info

Product

Resources

About